SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .
21 noviembre 2022
Legend Biotech Gets FDA Clearance for Small Cell Lung Cancer Trial .
Nov. 21, 2022 at 9:17 a.m. ET
By Sabela Ojea
The company, engaged in the discovery and development of novel cell therapies for oncology and other indications, said the Phase 1 trial for its LB2102 drug is designed to evaluate the safety and preliminary efficacy of the treatment while seeking to determine the recommended dose for a Phase 2 trial . ...
Suscribirse a:
Comentarios (Atom)






.jpeg)
